WO2026126144 - XANOMELINE COMBINATIONS FOR TREATING NEUROLOGICAL DISORDERS
National phase entry is expected:
Publication Number
WO/2026/126144
Publication Date
18.06.2026
International Application No.
PCT/IB2025/062744
International Filing Date
11.12.2025
Title **
[English]
XANOMELINE COMBINATIONS FOR TREATING NEUROLOGICAL DISORDERS
[French]
ASSOCIATIONS DE XANOMÉLINE POUR LE TRAITEMENT DE TROUBLES NEUROLOGIQUES
Applicants **
SYREMIS THERAPEUTICS LTD.
Inventors
KAGAN, Elena
Priority Data
63/733,023
12.12.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2959 | |
| EPO | Filing, Examination, Granting | 11803 | |
| Japan | Filing, Examination, Granting | 2170 | |
| South Korea | Filing, Examination, Granting | 2060 | |
| USA | Filing, Examination, Granting | 8040 |
Total:
27,032
Contact Us
Abstract[English]
The present invention relates to new compositions containing xanomeline and a CYP2D6 inhibitor. The present invention also relate to the use of xanomeline and a CYP2D6 inhibitor to increase a subject's xanomeline plasma concentrations. The present invention also relate to the use of xanomeline and a CYP2D6 inhibitor for treating disease including neurological disorders, such as psychosis and schizophrenia.[French]
La présente invention concerne de nouvelles compositions contenant de la xanoméline et un inhibiteur du CYP2D6. La présente invention concerne également l'utilisation de la xanoméline et d'un inhibiteur du CYP2D6 pour augmenter les concentrations plasmatiques de xanoméline chez un sujet. La présente invention concerne également l'utilisation de la xanoméline et d'un inhibiteur du CYP2D6 pour le traitement de maladies comprenant des troubles neurologiques, tels que la psychose et la schizophrénie.